Danielle Papincak, DO
Internal Medicine · Vandergrift, PANPI 1316408404
Payments from drug & device makers
Across 155 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$523
- Novo Nordisk$383
- Lilly USA, LLC$297
- Pfizer$233
- AbbVie$183
- Boehringer Ingelheim$178
- plus $824 from 18 others
What the payments were for
- Food & beverage$2,58199%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $523 |
| Novo Nordisk | 24 | $383 |
| Lilly USA, LLC | 20 | $297 |
| Pfizer | 14 | $233 |
| AbbVie | 13 | $183 |
| Boehringer Ingelheim | 11 | $178 |
| AstraZeneca | 9 | $156 |
| Amgen | 8 | $128 |
| Currax Pharmaceuticals LLC | 5 | $85 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Merck | 3 | $52 |
| Bayer | 3 | $48 |
| Astellas Pharma US Inc | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
How this compares
$2,620 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $119,124 |
| JardianceEmpagliflozin | 115 | $115,175 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $105,327 |
| OzempicSemaglutide | 89 | $96,357 |
| XareltoRivaroxaban | 58 | $43,560 |
| TrulicityDulaglutide | 44 | $41,346 |
| LinzessLinaclotide | 38 | $28,698 |
| MounjaroTirzepatide | 19 | $24,420 |
| Nurtec OdtRimegepant Sulfate | 12 | $23,752 |
| JanuviaSitagliptin Phosphate | 19 | $21,562 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $21,430 |
| TradjentaLinagliptin | 22 | $18,667 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $15,252 |
| MyrbetriqMirabegron | 25 | $14,741 |
| Repatha SureclickEvolocumab | 20 | $14,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $178 | $149,094160 claims |
| PfizerEliquis, Nurtec Odt | $233 | $142,876142 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $523 | $126,756165 claims |
| Novo NordiskOzempic | $383 | $96,35789 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $297 | $65,76663 claims |
| AbbVieLinzess, Synthroid | $183 | $30,39090 claims |
| MerckJanuvia | $52 | $21,56219 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $14,74125 claims |
| NovartisEntresto | $19 | $10,54916 claims |
| AstraZenecaBrilinta | $156 | $8,45112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Vandergrift
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.